Skip to content
Teethgrinder – Lifestyle
Author:
AEON Biopharma Inc
AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450
September 30, 2026
AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX®
September 9, 2026
AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer
August 24, 2026
AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX®
August 19, 2026
AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 12, 2026
AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards
August 3, 2026
AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding
July 14, 2026
AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society
June 4, 2026
AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 14, 2026
AEON Biopharma Sets Annual Shareholder Meeting
April 24, 2026
1
2
Next Page
→